Clarity says 67Cu-SAR-bisPSMA shows 63% PSA50 response at 8 GBq

Preliminary SECuRE trial data in 19 participants showed 81% disease control and five complete response or undetectable disease cases at the 8 GBq dose cohort.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.